Cargando…
Targeting anaplastic lymphoma kinase in neuroblastoma
Over the last decade, anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase (RTK), has been identified as a fusion partner in a diverse variety of translocation events resulting in oncogenic signaling in many different cancer types. In tumors where the full‐length ALK RTK itself is mutated, s...
Autores principales: | Umapathy, Ganesh, Mendoza‐Garcia, Patricia, Hallberg, Bengt, Palmer, Ruth H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850425/ https://www.ncbi.nlm.nih.gov/pubmed/30803032 http://dx.doi.org/10.1111/apm.12940 |
Ejemplares similares
-
Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells
por: Alam, Muhammad Wasi, et al.
Publicado: (2019) -
Anaplastic lymphoma kinase: signalling in development and disease
por: Palmer, Ruth H., et al.
Publicado: (2009) -
FAM150A and FAM150B are activating ligands for anaplastic lymphoma kinase
por: Guan, Jikui, et al.
Publicado: (2015) -
Sustained Response to Entrectinib in an Infant With a Germline ALKAL2 Variant and Refractory Metastatic Neuroblastoma With Chromosomal 2p Gain and Anaplastic Lymphoma Kinase and Tropomyosin Receptor Kinase Activation
por: Treis, Diana, et al.
Publicado: (2022) -
Phosphoproteomic analysis of anaplastic lymphoma kinase (ALK) downstream signaling pathways identifies signal transducer and activator of transcription 3 as a functional target of activated ALK in neuroblastoma cells
por: Sattu, Kamaraj, et al.
Publicado: (2013)